KEY POINTS
- This retrospective dosimetric study evaluated 30 patients previously treated with spatially fractionated radiotherapy (SFRT) for large, unresectable tumors, including 10 head and neck, 10 thoracic, and 10 abdominal/pelvic cases. Mean tumor diameter was 11.3 cm (range 8.6–16.2 cm), and mean GTV was 1,023.9 cm³ (range 336.5–2,758.9 cm³). Investigators explored whether a second SFRT treatment with deliberately staggered high-dose regions could improve biological dose distribution in tumors inadequately responding to initial treatment.
- The proposed approach consisted of two spatially fractionated treatments, each with a nominal maximum dose of 15 Gy, rather than repeating the same spatial high-dose pattern. Six treatment schemes were investigated, combining two initial lattice-placement strategies with second-treatment target regions generated by subtracting the 30%, 40%, or 50% isodose volume of the first treatment from the GTV. Each lattice used 1.5-cm-diameter high-dose spheres, optimized with four 6-MV FFF VMAT arcs, and the resulting plans were compared with the original clinically delivered single-fraction MLC-based SFRT plans.
- The best-performing approach was treatment scheme 3, which combined optimized Rödl Nibble sphere placement with a second lattice generated from the GTV minus the first treatment's 50% isodose volume. Mean GTV biologically effective dose (BED10) increased from 12.75 Gy in the original clinical plans to 21.44 Gy (difference +8.69 Gy; p<0.001). Near-minimum tumor BED also increased substantially: D95 from 2.83 to 10.60 Gy (+7.77 Gy; p<0.001) and D90 from 4.02 to 12.79 Gy (+8.77 Gy; p<0.001).
- Improvements extended to higher-dose regions within the tumor. With scheme 3, mean GTV BED D5 increased from 29.64 to 39.23 Gy (+9.59 Gy; p<0.001), D10 from 24.90 to 32.97 Gy (+8.07 Gy; p<0.001), and D50 from 10.90 to 19.18 Gy (+8.28 Gy; p<0.001). The second-best approach also used the 50% isodose subtraction but employed conventional lattice placement for the initial course. However, the higher cumulative tumor BED must be interpreted in the context of adding a second irradiation course, not as proof that staggering alone improves dose delivery or tumor control.
- Intermediate-dose spillage outside the target decreased with all six staggered schemes compared with the original clinical plans. For scheme 3, mean BED D2cm decreased from 44.94 to 33.57 Gy (p=0.018), despite the additional planned treatment. Nevertheless, the original clinical plans used forward-planned MLC-based SFRT, whereas the proposed two-course plans used inverse-planned VMAT; therefore, improved dose conformity and reduced spillage cannot be attributed exclusively to the staggered spatial arrangement.
- Spinal cord exposure increased significantly in head and neck plans, representing the principal safety concern. With scheme 3, mean maximum spinal cord EQD2 increased from 3.53 to 8.51 Gy (p=0.019), and all six staggered approaches produced significant increases in this structure. In contrast, maximum OAR doses in the thoracic and abdominal/pelvic cohorts did not show statistically significant increases; for scheme 3, mean maximum bowel and bladder EQD2 in pelvic cases were 11.18 and 9.48 Gy, compared with 13.03 and 12.56 Gy in the original plans. These comparisons involved only ten patients per anatomical group.
- The study evaluated virtual two-course treatment plans, not clinically delivered retreatment, and therefore provides no evidence of improved tumor response, symptom relief, local control, or treatment-related toxicity. Both planned courses used the same CT anatomy, without accounting for tumor deformation, growth, or regression between treatments. BED and EQD2 were calculated using the linear-quadratic model despite very high doses per fraction, creating additional radiobiological uncertainty; the optimal interval between courses and cumulative effects of subsequent conventional RT also remain undefined.
CLINICAL TAKEAWAY
Spatially staggered lattice radiotherapy may offer a technically feasible approach to redistributing high-dose regions during repeated treatment of bulky, radioresistant tumors, with the most favorable simulated dosimetric trade-offs observed in abdominal and pelvic cases. However, the addition of a second treatment course, increased spinal cord dose in head and neck plans, and uncertainty in high-dose biological modeling mean that this remains an experimental planning strategy rather than a validated salvage treatment.